Welcome to our dedicated page for IPSEN SA S/ADR news (Ticker: IPSEY), a resource for investors and traders seeking the latest updates and insights on IPSEN SA S/ADR stock.
IPSEN SA S/ADR (IPSEY) is a global biopharmaceutical company focused on transformative medicines in oncology, rare disease, and neuroscience. Recently, they have achieved Health Canada approval for Bylvay™ (odevixibat) for treating pruritus in patients with Progressive Familial Intrahepatic Cholestasis (PFIC). Bylvay is a non-systemic ileal bile acid transport inhibitor offering new hope for patients with PFIC. The company is involved in multiregional partnerships to expand access to innovative therapies globally.
Ipsen (Euronext: IPN; ADR: IPSEY) has appointed Karen Witts as an independent member of its Board of Directors. Witts previously served as Group CFO at Compass Group Plc until October 2021, and has extensive experience in corporate finance, strategy, and risk management from her tenures at companies like Kingfisher Plc and Vodafone. This addition brings the board to fourteen directors, which includes six women. The upcoming Shareholders' Meeting in 2022 will seek approval for Witts' position, covering the term until 2025.
As of December 31, 2021, IPSEN's liquidity agreement with NATIXIS ODDO BHF reported a liquidity account holding 34,053 shares and €1,433,400.74. Initially, 12,751 shares and €3,137,935 were allocated when the agreement commenced. Between July 1 and December 31, 2021, a total of 1,350 buy and 1,425 sell transactions occurred, with trading volumes of 178,366 shares (€15,275,528.42) bought and 168,568 shares (€14,644,572.90) sold. IPSEN is a global biopharmaceutical company focused on Oncology, Neuroscience, and Rare Diseases, with sales exceeding €2.5bn in FY 2020.
This press release from Ipsen provides regulatory updates regarding its share capital and voting rights as of December 31, 2021. The total number of shares composing the share capital amounts to 83,814,526, while the gross total of voting rights is 132,125,842, and the net total of voting rights stands at 130,808,311. These figures are crucial for shareholders and potential investors, reflecting the company’s governance structure and compliance with French financial regulations.
Ipsen has secured global rights to develop and commercialize GENFIT's innovative treatment, elafibranor, aimed at Primary Biliary Cholangitis (PBC). The agreement provides GENFIT with an upfront payment of €120 million and potential milestone payments totaling €360 million, alongside royalties up to 20%. Ipsen will also acquire an 8% equity stake in GENFIT through a €28 million investment. The Phase III trial, ELATIVE™, is ongoing, with top-line data expected in early 2023, presenting a significant opportunity for both companies in addressing unmet medical needs in liver diseases.
Ipsen released regulatory news on November 30, 2021, detailing its share capital structure. The total number of shares comprising the share capital is 83,814,526. The gross total of voting rights stood at 132,128,427, while the net total, after excluding non-voting shares, was 130,814,971. This information is in compliance with the French Commercial Code and the regulations of the Autorité des Marchés Financiers.
Ipsen announced the total number of shares and voting rights on 31 October 2021. The total number of shares composing the share capital is 83,814,526. The gross total of voting rights stands at 132,139,463, while the net total of voting rights is 130,824,193. This update is in accordance with the French Commercial Code, emphasizing the necessity to declare threshold crossing in compliance with legal requirements.
Ipsen has appointed Stewart Campbell as Executive Vice President and President of North America, effective immediately. He will lead Ipsen's operations in the US and Canada and will report to CEO David Loew. Campbell, who joined Ipsen in 2021, brings over 20 years of pharmaceutical experience, including significant roles at Roche/Genentech. His leadership is expected to enhance Ipsen's growth in North America as the company continues to execute its new group strategy aimed at improving patient outcomes.
Ipsen (Euronext: IPN; ADR: IPSEY) reported strong sales for Q3 2021, achieving total sales of €727.4 million, up 14.9% year-over-year. Year-to-date sales reached €2,077.7 million, a 9.3% increase. Specialty Care sales grew 12.5% to €1,912.3 million, driven by Somatuline, Cabometyx, and Dysport. Consumer Healthcare also saw a 9.8% rise. Full-year sales growth guidance is upgraded to over 11.0% from 8.0%. Despite a regulatory setback for palovarotene, business development remains strong, evidenced by recent collaborations in Oncology and Neuroscience.
Ipsen has secured an exclusive worldwide license with Accent Therapeutics to develop and commercialize a pre-clinical METTL3-inhibitor program, targeting acute myeloid leukemia (AML). This collaboration enhances Ipsen's oncology pipeline and expands its focus on hematological malignancies. Ipsen will invest up to $446 million, including upfront and milestone payments, plus royalties. This agreement aligns with Ipsen's mission to address high unmet medical needs in oncology, specifically for rare cancers.
FAQ
What is the current stock price of IPSEN SA S/ADR (IPSEY)?
What is the market cap of IPSEN SA S/ADR (IPSEY)?
What is IPSEN SA S/ADR focused on?
What recent achievement has IPSEN SA S/ADR made?
What is Bylvay™ (odevixibat)?
What are IPSEN SA S/ADR's partnerships focused on?
